FAHFAs for Type 1 Diabetes Beta-Cell Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 1 diabetes are invasive, require strict regimens, and come with significant complications, necessitating a safer and more effective approach to prevent, delay, or treat the condition and its associated complications.
Innovation Solution
Administration of fatty acid esters of hydroxy fatty acids (FAHFAs) or their pharmaceutically acceptable salts to treat type 1 diabetes, inhibit cytokine-induced apoptosis, promote β-cell viability and proliferation, and stimulate insulin secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard insulin injection therapy is used to treat type 1 diabetes, then blood sugar control is achieved, but patient compliance becomes difficult and severe complications occur
Solution Approach 1:
The patent employs FAHFAs that naturally occur in the human body and diet, enabling the body's own metabolic pathways to regulate blood sugar. This self-service approach eliminates the need for external insulin injections and complex monitoring regimens, thereby improving patient compliance while maintaining blood sugar control reliability
Solution Approach 2:
The invention changes the therapeutic parameter from exogenous insulin administration to endogenous FAHFA activation. By utilizing naturally occurring fatty acid esters of hydroxy fatty acids, the treatment shifts from a complex injection-based regimen to a simpler dietary supplement approach, improving ease of operation while achieving comparable or superior glycemic control
2Reliability
If frequent blood sugar measurement and insulin adjustment are implemented, then glycemic control improves, but treatment complexity and patient burden increase
Solution Approach 1:
FAHFAs activate endogenous mechanisms that automatically regulate blood sugar levels without requiring frequent manual measurements and adjustments. The body's natural response to FAHFA supplementation provides continuous, self-regulating glycemic control, dramatically simplifying the treatment regimen while maintaining reliability
Solution Approach 2:
The invention extracts and utilizes the beneficial metabolic effects of naturally occurring FAHFAs that are already present in the human body and diet. By isolating and supplementing these specific compounds, the patent removes the need for complex insulin therapy protocols while preserving effective blood sugar regulation
3Duration of action of stationary object
If long-term insulin therapy is administered to manage type 1 diabetes, then survival is extended, but risk of severe complications including blindness, kidney failure, and cardiovascular disease increases
Solution Approach 1:
The patent converts the potentially harmful effects of long-term insulin therapy into beneficial outcomes by using FAHFAs that activate protective endogenous pathways. FAHFAs not only control blood sugar but also reduce inflammation, protect pancreatic beta cells, and prevent the severe complications associated with conventional insulin therapy, thereby extending life expectancy without increasing complication risk
Solution Approach 2:
FAHFAs provide preliminary protection against the harmful effects of diabetes and its treatment by activating protective mechanisms before complications can develop. The compounds prevent beta cell death, reduce inflammatory damage, and protect vascular systems, thereby preventing blindness, kidney failure, and cardiovascular disease before they occur
Data Source
AI summary
Provided herein are methods for treating type 1 diabetes and its sequelae (e.g., cardiovascular, renal or neurologic diseases for which type 1 diabetes is a risk factor) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a fatty acid ester of a hydroxy fatty acid (FAHFA), or a pharmaceutically acceptable salt thereof.